ZNTL

Company Overview — What Does Zentalis Pharmaceuticals, Inc. Do?

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its lead product candidate includes the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; Phase 1/2 clinical trial for the treatment of advanced solid tumors as a monotherapy and in an ongoing Phase 1b clinical trial in combination with chemotherapy in patients with platinum resistant ovarian cancer; and Phase 2 monotherapy trial for a tumor agnostic, predictive biomarker. The company's other lead product candidate includes ZN-c5, an oral selective estrogen receptor degrader that is in a Phase 1/2 clinical trial for the treatment of advanced estrogen receptor-positive, human epidermal growth factor receptor 2-negative, or advanced or metastatic breast cancer. In addition, it is involved in developing ZN-d5, a selective inhibitor of B-cell lymphoma 2 that is in a Phase 1 clinical trial for the treatment of non-Hodgkin's lymphoma and acute myelogenous leukemia; and ZN-e4, an irreversible inhibitor of mutant epidermal growth factor receptor, which is in Phase 1/2 clinical trial for the treatment of advanced non-small cell lung cancer. Further, the company is developing BCL-xL heterobifunctional degraders based on E3 ligases not expressed in platelets, allowing for the avoidance of dose-limiting thrombocytopenia associated with BCL-xL inhibitors. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Mayo Foundation for Medical Education and Research; SciClone Pharmaceuticals International (Cayman) Development Ltd.; Pfizer, Inc.; Eli Lilly and Company; GlaxoSmithKline, and Zentera Therapeutics (Cayman), Ltd. The company was incorporated in 2014 and is based in New York, New York. Zentalis Pharmaceuticals, Inc. (ZNTL) is classified as a micro-cap stock in the Healthcare sector, specifically within the Pharmaceutical Products industry. The company is led by CEO Kimberly L. Blackwell and employs approximately 160 people, headquartered in New York, California. With a market capitalization of $182M, ZNTL is one of the notable companies in the Healthcare sector.

Zentalis Pharmaceuticals, Inc. (ZNTL) Stock Rating — Reduce (April 2026)

As of April 2026, Zentalis Pharmaceuticals, Inc. receives a Reduce rating with a composite score of 33.0/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.ZNTL ranks #2,519 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Zentalis Pharmaceuticals, Inc. ranks #323 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

ZNTL Stock Price and 52-Week Range

Zentalis Pharmaceuticals, Inc. (ZNTL) currently trades at $6.74. The stock gained $2.32 (52.5%) in the most recent trading session. The 52-week high for ZNTL is $3.95, which means the stock is currently trading 70.6% from its annual peak. The 52-week low is $1.01, putting the stock 567.2% above its annual trough. Recent trading volume was 46.3M shares, indicating strong institutional interest and high liquidity.

Is ZNTL Overvalued or Undervalued? — Valuation Analysis

Zentalis Pharmaceuticals, Inc. (ZNTL) carries a value factor score of 11/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 0.88x, versus the sector average of 2.75x.

At current multiples, Zentalis Pharmaceuticals, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Zentalis Pharmaceuticals, Inc. Profitability — ROE, Margins, and Quality Score

Zentalis Pharmaceuticals, Inc. (ZNTL) earns a quality factor score of 22/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -65.7%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -49.1% versus the sector average of -33.1%.

Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

ZNTL Debt, Balance Sheet, and Financial Health

Zentalis Pharmaceuticals, Inc. has a debt-to-equity ratio of 34.0%, compared to the Healthcare sector average of 32.0%. The low leverage indicates a conservative balance sheet with significant financial flexibility. The current ratio is 6.93x, indicating strong short-term liquidity. Total debt on the balance sheet is $0. Cash and equivalents stand at $39M.

ZNTL has a beta of 1.72, meaning it is more volatile than the broader market — a $10,000 investment in ZNTL would be expected to move 71.7% more than the S&P 500 on any given day. The stability factor score for Zentalis Pharmaceuticals, Inc. is 19/100, suggesting elevated price swings that may be unsuitable for conservative portfolios.

Zentalis Pharmaceuticals, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Zentalis Pharmaceuticals, Inc. reported revenue of $0 and earnings per share (EPS) of $-1.91. Net income for the quarter was $-142M. Operating income came in at $-167M.

In FY 2025, Zentalis Pharmaceuticals, Inc. reported revenue of $0 and earnings per share (EPS) of $-1.91. Net income for the quarter was $-137M. Operating income came in at $-153M.

In Q3 2025, Zentalis Pharmaceuticals, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.37. Net income for the quarter was $-27M. Operating income came in at $-34M.

In Q2 2025, Zentalis Pharmaceuticals, Inc. reported revenue of $0 and earnings per share (EPS) of $-0.37. Net income for the quarter was $-27M. Operating income came in at $-36M.

Over the past 8 quarters, Zentalis Pharmaceuticals, Inc. has experienced revenue contraction from $0 to $0. Investors analyzing ZNTL stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

ZNTL Dividend Yield and Income Analysis

Zentalis Pharmaceuticals, Inc. (ZNTL) does not currently pay a dividend. This is common among smaller companies in the Pharmaceutical Products industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

ZNTL Momentum and Technical Analysis Profile

Zentalis Pharmaceuticals, Inc. (ZNTL) has a momentum factor score of 64/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 25/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 44/100 reflects moderate short selling activity.

ZNTL vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Zentalis Pharmaceuticals, Inc. (ZNTL) ranks #323 out of 838 stocks based on the Blank Capital composite score. This places ZNTL in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing ZNTL against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full ZNTL vs S&P 500 (SPY) comparison to assess how Zentalis Pharmaceuticals, Inc. stacks up against the broader market across all factor dimensions.

ZNTL Next Earnings Date

No upcoming earnings date has been announced for Zentalis Pharmaceuticals, Inc. (ZNTL) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy ZNTL? — Investment Thesis Summary

The quantitative profile for Zentalis Pharmaceuticals, Inc. suggests caution. The quality score of 22/100 flags below-average profitability. The value score of 11/100 indicates premium valuation. Price momentum is positive at 64/100, suggesting the trend favors buyers. High volatility (stability score 19/100) increases portfolio risk.

In summary, Zentalis Pharmaceuticals, Inc. (ZNTL) earns a Reduce rating with a composite score of 33.0/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on ZNTL stock.

Related Resources for ZNTL Investors

Explore more research and tools: ZNTL vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare ZNTL head-to-head with peers: ZNTL vs AZN, ZNTL vs SLGL, ZNTL vs VMD.